Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 7, 2018; 24(21): 2236-2246
Published online Jun 7, 2018. doi: 10.3748/wjg.v24.i21.2236
Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells
Ting-Ting Li, Hao Liu, Jiang Yu, Guang-Yao Shi, Li-Ying Zhao, Guo-Xin Li
Ting-Ting Li, Hao Liu, Jiang Yu, Li-Ying Zhao, Guo-Xin Li, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Guang-Yao Shi, Division of Cardiology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China
Author contributions: Li TT, Liu H and Yu J contributed equally to the design and preparation of this study and should be considered co-first authors; Yu J and Li GX designed the research; Li TT and Liu H contributed to data acquisition and writing of article; Zhao LY and Shi GY contributed to data analysis; Liu H, Yu J and Li GX contributed to editing, reviewing and final approval of article.
Supported by the Guangdong Provincial Natural Science Foundation, No. 2016A030313843.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Guo-Xin Li, MD, PhD, Professor, Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou 510515, Guangdong Province, China.
Telephone: +86-20-61641681 Fax: +86-20-62787626
Received: April 3, 2018
Peer-review started: April 4, 2018
First decision: April 19, 2018
Revised: April 27, 2018
Accepted: May 18, 2018
Article in press: May 18, 2018
Published online: June 7, 2018

Gastric cancer (GC), with its high incidence and mortality rates, is a highly fatal cancer that is common in East Asia particularly in China. Its recurrence and metastasis are the main causes of its poor prognosis. Circulating tumor cells (CTCs) or other blood biomarkers that are released into the circulating blood stream by tumors are thought to play a crucial role in the recurrence and metastasis of gastric cancer. Therefore, the detection of CTCs and other blood biomarkers has an important clinical significance; in fact, they can help predict the prognosis, assess the staging, monitor the therapeutic effects and determine the drug susceptibility. Recent research has identified many blood biomarkers in GC, such as various serum proteins, autoantibodies against tumor associated antigens, and cell-free DNAs. The analysis of CTCs and circulating cell-free tumor DNA (ctDNA) in the peripheral blood of patients with gastric cancer is called as liquid biopsy. These blood biomarkers provide the disease status for individuals and have clinical meaning. In this review, we focus on the recent scientific advances regarding CTCs and other blood biomarkers, and discuss their origins and clinical meaning.

Keywords: Gastric cancer, Biomarker, Circulating tumor cells, Autoantibodies, Cell-free DNA

Core tip: As liquid biopsy, the detection of circulating tumor cells (CTCs) and other blood biomarkers have their certain clinical significance. In this review, we focus on the recent scientific advances of CTCs and some other blood biomarkers, and discuss their origin and clinical usefulness.